"Fudan Subtyping" to be Commercialized to Enable Personalized Therapies of TNBC and Improve Treatment Outcome
DEQING, CHINA, March 7, 2023 /EINPresswire.com/ -- On March 3 TNBC Day, Shuwen Biotech, an integrated in vitro diagnostic company with focus on breast cancer and women’s health, announced that it has acquired from Fudan University Shanghai Cancer Center (FUSCC) patents covering the “Fudan Subtyping,” a breakthrough in molecular subtyping of triple-negative breast cancer (TNBC) that significantly improves treatment outcome of TNBC. Shuwen has also formed research collaboration with the Center to develop and commercialize the technology.
TNBC is the most challenging type of breast cancer, exhibiting greater aggressiveness and absence of targeted therapies. While TNBC is often treated as a single disease, its intrinsic heterogeneity has been recognized. Based on research with clinical, genomic, and transcriptomic analysis of primary TNBC cohorts, Professors Zhiming Shao and Yizhou Jiang and their colleagues at FUSCC developed the “Fudan Subtyping” system classifying TNBCs into four transcriptome-based subtypes with putative therapeutic targets: (1) luminal androgen receptor (LAR), (2) immunomodulatory (IM), (3) basal-like immune-suppressed (BLIS), and (4) mesenchymal-like (MES). The Fudan Subtyping was employed in two prospective clinical trials. The FUTURE trial demonstrated personalized treatment of heavily pretreated refractory metastatic TNBCs based on Fudan Subtyping led to significantly improved outcomes with an ORR of 29.0% as compared to about 10% in traditional treatment. In the FUTURE-C-PLUS trial, a first-line immunotherapy of TNBC patients with unresectable locally advanced or metastatic IM subtype yielded an ORR of as high as 81.3%.
"With Fudan Subtyping along with our flagship product MammaTyper® we strive to provide physicians and patients the best molecular subtyping solutions in breast cancer."
— Jay Z. Zhang
“FUSCC is the world’s largest breast cancer treatment center with distinguished physicians and scientists conducting world-class breast cancer research,” commented Jay Z. Zhang, Chairman and CEO of Shuwen Biotech. “We are very happy to have secured the rights to the Fudan Subtyping technology and formed collaboration with Professor Shao’s group. Fudan Subtyping has the potential to significantly improve the TNBC treatment outcome, and we will work diligently to make it available to physicians and TNBC patients. With Fudan Subtyping along with our flagship product MammaTyper® we strive to provide physicians and patients the best molecular subtyping solutions in breast cancer.”
References:
Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35, e425 (2019).
Jiang, YZ., Liu, Y., Xiao, Y. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res 31, 178–186 (2021). https://doi.org/10.1038/s41422-020-0375-9
Wu, SY., Xu, Y., Chen, L. et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer 21, 84 (2022). https://doi.org/10.1186/s12943-022-01536-6.
About Shuwen Biotech
Shuwen Biotech is an integrated diagnostic company with offices in China and Germany. Founded on the principles of innovation, patent protection, and international collaboration, Shuwen established strategic partnerships with leading academic and commercial institutions to commercialize first-in-class diagnostic technologies and patents, and has developed a range of novel diagnostics in the fields of cancer and women’s health. Shuwen has also developed quality companion diagnostics and provided central lab biomarker testing services to leading pharmaceutical developers and hospitals. Shuwen houses an in-house development team, CAP-accredited central labs, and GMP/ISO13485-certified IVD manufacturing facilities, all in line with global standards to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health. Innovative products are offered on the international market through Cerca Biotech GmbH, Shuwen’s European subsidiary in Berlin.
